_id
691b20c83c536f8df2318da7
Ticker
RLF.SW
Name
Relief Therapeutics Holding AG
Exchange
SW
Address
Avenue de Secheron 15, Geneva, Switzerland, 1202
Country
Switzerland
Sector
Healthcare
Industry
Biotechnology
Currency
CHF
Website
https://www.relieftherapeutics.com
Description
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis. In addition, the company develops RLF-TD011, a hypochlorous acid solution for epidermolysis bullosa. Further, it is developing RLF-OD32, a next-generation liquid sapropterin formulation for phenylketonuria. The company operates in Switzerland, Europe, North America, and internationally. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.
Last Close
2.885
Volume
5930
Current Price
2.885
Change
0
Last Updated
2025-11-27T12:02:57.997Z
Image
https://logo.clearbit.com/www.relieftherapeutics.com
Ipo Date
-
Market Cap
35949932
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
1218000
Cost Of Revenue
599000
Gross Profit
619000
Operating Expenses
5044000
Operating Income
-4688000
Interest Expense
24000
Pretax Income
-4504000
Net Income
-4478000
Eps
-0.35673867243184404
Dividends Per Share
-
Shares Outstanding
12591919
Income Tax Expense
26000
EBITDA
-4015000
Operating Margin
-384.8932676518884
Total Other Income Expense Net
184000
Cash
12500000
Short Term Investments
-
Receivables
1468000
Inventories
923000
Total Current Assets
15189000
Property Plant Equipment
2110000
Total Assets
47987000
Payables
620000
Short Term Debt
369000
Long Term Debt
-
Total Liabilities
15354000
Equity
32633000
Depreciation
747000
Change In Working Capital
789000
Cash From Operations
-3760000
Capital Expenditures
12000
Cash From Investing
1288000
Cash From Financing
-57000
Net Change In Cash
-2580000
PE
-
PB
1.1097437658198757
ROE
-13.722305641528514
ROA
-9.331694000458457
FCF
-3772000
Fcf Percent
-3.09688013136289
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
3
Quality Investing Score
2.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
1218000
Quarters > 0 > income Statement > cost Of Revenue
599000
Quarters > 0 > income Statement > gross Profit
619000
Quarters > 0 > income Statement > operating Expenses
5044000
Quarters > 0 > income Statement > operating Income
-4688000
Quarters > 0 > income Statement > interest Expense
24000
Quarters > 0 > income Statement > pretax Income
-4504000
Quarters > 0 > income Statement > net Income
-4478000
Quarters > 0 > income Statement > eps
-0.35673867243184404
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
12552606
Quarters > 0 > income Statement > income Tax Expense
26000
Quarters > 0 > income Statement > EBITDA
-4015000
Quarters > 0 > income Statement > operating Margin
-384.8932676518884
Quarters > 0 > income Statement > total Other Income Expense Net
184000
Quarters > 0 > balance Sheet > cash
12500000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
1468000
Quarters > 0 > balance Sheet > inventories
923000
Quarters > 0 > balance Sheet > total Current Assets
15189000
Quarters > 0 > balance Sheet > property Plant Equipment
2110000
Quarters > 0 > balance Sheet > total Assets
47987000
Quarters > 0 > balance Sheet > payables
620000
Quarters > 0 > balance Sheet > short Term Debt
369000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
15354000
Quarters > 0 > balance Sheet > equity
32633000
Quarters > 0 > cash Flow > net Income
-4478000
Quarters > 0 > cash Flow > depreciation
747000
Quarters > 0 > cash Flow > change In Working Capital
789000
Quarters > 0 > cash Flow > cash From Operations
-3760000
Quarters > 0 > cash Flow > capital Expenditures
12000
Quarters > 0 > cash Flow > cash From Investing
1288000
Quarters > 0 > cash Flow > cash From Financing
-57000
Quarters > 0 > cash Flow > net Change In Cash
-2580000
Quarters > 0 > ratios > PE
-0.35673867243184404
Quarters > 0 > ratios > PB
1.1097437658198757
Quarters > 0 > ratios > ROE
-13.722305641528514
Quarters > 0 > ratios > ROA
-9.331694000458457
Quarters > 0 > ratios > FCF
-3772000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-3.09688013136289
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
2836000
Quarters > 1 > income Statement > cost Of Revenue
4632000
Quarters > 1 > income Statement > gross Profit
-1796000
Quarters > 1 > income Statement > operating Expenses
1822000
Quarters > 1 > income Statement > operating Income
-3618000
Quarters > 1 > income Statement > interest Expense
28000
Quarters > 1 > income Statement > pretax Income
-15359000
Quarters > 1 > income Statement > net Income
-12562000
Quarters > 1 > income Statement > eps
-1.0017543859649123
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
12540000
Quarters > 1 > income Statement > income Tax Expense
-2797000
Quarters > 1 > income Statement > EBITDA
-14208000
Quarters > 1 > income Statement > operating Margin
-127.574047954866
Quarters > 1 > income Statement > total Other Income Expense Net
-11741000
Quarters > 1 > balance Sheet > cash
15080000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
2029000
Quarters > 1 > balance Sheet > inventories
1042000
Quarters > 1 > balance Sheet > total Current Assets
19688000
Quarters > 1 > balance Sheet > property Plant Equipment
2396000
Quarters > 1 > balance Sheet > total Assets
53224000
Quarters > 1 > balance Sheet > payables
1627000
Quarters > 1 > balance Sheet > short Term Debt
960000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
16560000
Quarters > 1 > balance Sheet > equity
36664000
Quarters > 1 > cash Flow > net Income
-12562000
Quarters > 1 > cash Flow > depreciation
1123000
Quarters > 1 > cash Flow > change In Working Capital
3077000
Quarters > 1 > cash Flow > cash From Operations
359000
Quarters > 1 > cash Flow > capital Expenditures
14000
Quarters > 1 > cash Flow > cash From Investing
4299000
Quarters > 1 > cash Flow > cash From Financing
-246000
Quarters > 1 > cash Flow > net Change In Cash
4352000
Quarters > 1 > ratios > PE
-1.0017543859649123
Quarters > 1 > ratios > PB
0.9867417630373118
Quarters > 1 > ratios > ROE
-34.262491817586735
Quarters > 1 > ratios > ROA
-23.602134375469713
Quarters > 1 > ratios > FCF
345000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
0.12165021156558534
Quarters > 1 > health Score
45
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
5581000
Quarters > 2 > income Statement > cost Of Revenue
6484000
Quarters > 2 > income Statement > gross Profit
-903000
Quarters > 2 > income Statement > operating Expenses
3148000
Quarters > 2 > income Statement > operating Income
-4051000
Quarters > 2 > income Statement > interest Expense
41000
Quarters > 2 > income Statement > pretax Income
-3997000
Quarters > 2 > income Statement > net Income
-4557000
Quarters > 2 > income Statement > eps
-0.3633971291866029
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
12540000
Quarters > 2 > income Statement > income Tax Expense
560000
Quarters > 2 > income Statement > EBITDA
-2518000
Quarters > 2 > income Statement > operating Margin
-72.58555814370185
Quarters > 2 > income Statement > total Other Income Expense Net
54000
Quarters > 2 > balance Sheet > cash
10728000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
2937000
Quarters > 2 > balance Sheet > inventories
374000
Quarters > 2 > balance Sheet > total Current Assets
14711000
Quarters > 2 > balance Sheet > property Plant Equipment
2701000
Quarters > 2 > balance Sheet > total Assets
70921000
Quarters > 2 > balance Sheet > payables
1291000
Quarters > 2 > balance Sheet > short Term Debt
398000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
21654000
Quarters > 2 > balance Sheet > equity
49267000
Quarters > 2 > cash Flow > net Income
-4557000
Quarters > 2 > cash Flow > depreciation
1438000
Quarters > 2 > cash Flow > change In Working Capital
-398000
Quarters > 2 > cash Flow > cash From Operations
-3087000
Quarters > 2 > cash Flow > capital Expenditures
86000
Quarters > 2 > cash Flow > cash From Investing
-86000
Quarters > 2 > cash Flow > cash From Financing
-616000
Quarters > 2 > cash Flow > net Change In Cash
-3828000
Quarters > 2 > ratios > PE
-0.3633971291866029
Quarters > 2 > ratios > PB
0.7343231777863478
Quarters > 2 > ratios > ROE
-9.24959912314531
Quarters > 2 > ratios > ROA
-6.425459313884463
Quarters > 2 > ratios > FCF
-3173000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.5685361046407453
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
3010000
Quarters > 3 > income Statement > cost Of Revenue
8150000
Quarters > 3 > income Statement > gross Profit
-5140000
Quarters > 3 > income Statement > operating Expenses
3118000
Quarters > 3 > income Statement > operating Income
-8258000
Quarters > 3 > income Statement > interest Expense
75000
Quarters > 3 > income Statement > pretax Income
-47542000
Quarters > 3 > income Statement > net Income
-41682000
Quarters > 3 > income Statement > eps
-3.3239234449760766
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
12540000
Quarters > 3 > income Statement > income Tax Expense
-5860000
Quarters > 3 > income Statement > EBITDA
-45853000
Quarters > 3 > income Statement > operating Margin
-274.3521594684385
Quarters > 3 > income Statement > total Other Income Expense Net
-39284000
Quarters > 3 > balance Sheet > cash
14556000
Quarters > 3 > balance Sheet > short Term Investments
9000
Quarters > 3 > balance Sheet > receivables
2837000
Quarters > 3 > balance Sheet > inventories
557000
Quarters > 3 > balance Sheet > total Current Assets
18304000
Quarters > 3 > balance Sheet > property Plant Equipment
2967000
Quarters > 3 > balance Sheet > total Assets
76390000
Quarters > 3 > balance Sheet > payables
1025000
Quarters > 3 > balance Sheet > short Term Debt
2216000
Quarters > 3 > balance Sheet > long Term Debt
9000
Quarters > 3 > balance Sheet > total Liabilities
24162000
Quarters > 3 > balance Sheet > equity
52228000
Quarters > 3 > cash Flow > net Income
-41682000
Quarters > 3 > cash Flow > depreciation
1614000
Quarters > 3 > cash Flow > change In Working Capital
-47000
Quarters > 3 > cash Flow > cash From Operations
-7053000
Quarters > 3 > cash Flow > capital Expenditures
77000
Quarters > 3 > cash Flow > cash From Investing
8822000
Quarters > 3 > cash Flow > cash From Financing
-124000
Quarters > 3 > cash Flow > net Change In Cash
1764000
Quarters > 3 > ratios > PE
-3.3239234449760766
Quarters > 3 > ratios > PB
0.6926916596461667
Quarters > 3 > ratios > ROE
-79.80776594929922
Quarters > 3 > ratios > ROA
-54.56473360387485
Quarters > 3 > ratios > FCF
-7130000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-2.3687707641196014
Quarters > 3 > health Score
34
Valuation > metrics > PE
-0.35673867243184404
Valuation > metrics > PB
1.1097437658198757
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-13.722305641528514
Profitability > metrics > ROA
-29.48186187372441
Profitability > metrics > Net Margin
-3.676518883415435
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.47050531670395
Risk > metrics > Interest Coverage
-195.33333333333334
Risk > final Score
-721
Risk > verdict
High
Liquidity > metrics > Current Ratio
15.35793731041456
Liquidity > metrics > Quick Ratio
14.424671385237614
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-457
Prev Risks > 1
-335
Prev Risks > 2
-380
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:11:33.820Z
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis. In addition, the company develops RLF-TD011, a hypochlorous acid solution for epidermolysis bullosa. Further, it is developing RLF-OD32, a next-generation liquid sapropterin formulation for phenylketonuria. The company operates in Switzerland, Europe, North America, and internationally. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.
Stock Price
CHF0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ARelief Therapeutics Shareholders Approve Business Combination with NeuroX Yahoo Finance
Read more →Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze Yahoo Finance
Read more →(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Relief Therapeutics Holding AG
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
CHF 0
Cost Of Revenue
CHF 0
Gross Profit
CHF 0
Operating Expenses
CHF 0
Operating Income
CHF 0
Interest Expense
CHF 0
Pretax Income
CHF 0
Net Income
CHF 0
Income Tax Expense
CHF 0
EBITDA
CHF 0
Total Other Income Expense Net
CHF 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
CHF 0
Short Term Investments
CHF 0
Receivables
CHF 0
Inventories
CHF 0
Total Current Assets
CHF 0
Property Plant Equipment
CHF 0
Total Assets
CHF 0
Payables
CHF 0
Short Term Debt
CHF 0
Long Term Debt
CHF 0
Total Liabilities
CHF 0
Equity
CHF 0
(Last Updated 2025-06-30)
Net Income
CHF 0
Depreciation
CHF 0
Change In Working Capital
CHF 0
Cash From Operations
CHF 0
Capital Expenditures
CHF 0
Cash From Investing
CHF 0
Cash From Financing
CHF 0
Net Change In Cash
CHF 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.